Skip to main content
Content Starts Here GSA Federal Advisory Committee Act (FACA) Database Skip to main content

Committee Detail

Hide Section - GENERAL INFORMATION

GENERAL INFORMATION

Committee NameNational Cancer Institute Board of Scientific AdvisorsAgency NameDepartment of Health and Human Services
Fiscal Year2019Committee Number1483
Original Establishment Date11/20/1985Committee StatusChartered
Actual Termination Date Committee URLhttp://deainfo.nci.nih.gov/advisory/bsa/bsa.htm
New Committee This FYNoPresidential Appointments*No
Terminated This FYNoMax Number of Members*35
Current Charter Date10/8/2019Designated Fed Officer Position Title*DIRECTOR, DIVISION OF EXTRAMURAL ACTIVITIES, NCI
Date Of Renewal Charter10/8/2021Designated Federal Officer Prefix
Projected Termination Date Designated Federal Officer First Name*PAULETTE
Exempt From Renewal*NoDesignated Federal Officer Middle NameS.
Specific Termination AuthorityDesignated Federal Officer Last Name*GRAY
Establishment Authority*Authorized by LawDesignated Federal Officer SuffixPH.D.
Specific Establishment Authority*42 U.S.C. 285a-2(b)(7)Designated Federal Officer Phone*240-276-6340
Effective Date Of Authority*11/20/1985Designated Federal Officer Fax*240-276-7815
Exempt From EO 13875 Discretionary CmteNot ApplicableDesignated Federal Officer Email*grayp@mail.nih.gov
Committee Type*Continuing
Presidential*No
Committee Function*Scientific Technical Program Advisory Board
Hide Section - RECOMMENDATION/JUSTIFICATIONS

RECOMMENDATION/JUSTIFICATIONS

Agency Recommendation*Continue
Legislation to Terminate RequiredNot Applicable
Legislation StatusNot Applicable
How does cmte accomplish its purpose?*The Board is composed of members who are distinguished scientists from outside the NCI and representatives from the advocacy community. The Board provides scientific advice on a wide variety of matters concerning scientific program policy, progress and future direction of the extramural research programs, and concept review of extramural program initiatives. This includes the evaluation of NCI awarded grants, oversight of concept review of cooperative agreements and contracts initiatives and those activities which it considers meritorious and consistent with the Institute’s programs. The advisory role of the Board is scientific and does not include deliberation on matters of public policy. In 2019, the BSA was presented reports on various topics related to cancer research in general as well as legislative matters. BSA members provided insights regarding a final report from the BSA ad hoc Working Group on Immunology of Therapies & Vaccines and Research Structure. As a result, they approved several recommendations centered on three main areas - understanding KSHV, obtaining cancer biospecimens from individuals infected with HIV, and promoting individual investigator-initiated research within the HIV malignancy field. The Board reviewed and deliberated on request for application (RFA) concepts covering a wide variety of topics including the following: Cellular Cancer Biology Imaging Research Resource Program (New RFA); Molecular and Biological Effects of High Linear Energy Transfer Radiation Exposure (New RFA); Informatics Technology for Cancer Research (New RFA/Cooperative Agreement [Coop. Agr.]); Optimizing Management and Outcomes for Cancer Survivors Transitioning to Follow-up Care (New RFA); Research on Pediatric, Adolescent, and Young Adult Survivorship Through the Childhood Cancer Survivorship, Treatment, Access and Research (STAR) Act (New RFA); Advancing Cancer Immunotherapy by Mitigating Immune-Related Adverse Events (New RFA); Patient Engagement for Priority Cancer Sequencing (PE4PC-Seq) (New RFA/Coop. Agr.); Cancer Intervention and Surveillance Modeling Network (CISNET) (Reissue RFA/Coop. Agr.); AIDS Malignancy Consortium (AMC) (Reissue RFA/Coop. Agr./Limited Competition); Next Gen Technology for Next Gen Cancer Models (New RFA/Coop. Agr.); Mechanisms of Cancer Drug Resistance Competing Revisions (New RFA); Pediatric Brain Tumor Consortium (Reissue RFA/Coop. Agr./Limited Competition); Chronic Pancreatitis, Diabetes, and Pancreatic Cancer Consortium (Reissue RFA/Coop. Agr.); U.S. and Low- and Middle-Income Country (LMIC) HIV Malignancy Research Networks (RFA/Coop. Agr.); and Biospecimen Banks to Support NCI National Clinical Trials Network (NCTN), NCI Community Oncology Research Program (NCORP), and CTEP-Supported Early Trials/Studies (Reissue RFA/Coop. Agr./Limited Competition).
How is membership balanced?*The Board consists of up to 35 members, including the Chair, appointed by the Director, NCI, from authorities knowledgeable in the fields of laboratory, clinical and biometric research, clinical cancer treatment, cancer etiology, and cancer prevention and control, with emphasis on training and experience in the various disciplines and fields related to scientific areas relevant to carcinogenesis, cancer biology and diagnosis, cancer center administration, medicine, radiological and surgical oncology, cancer chemotherapy, cancer epidemiology, cancer prevention and control, cancer education, cancer information services, community outreach, biological, chemical and physical carcinogenesis, DNA repair and effects, tumor biology and immunology, humoral and cellular immunity, hematopoiesis, cell differentiation and transformation, oncogenes and growth factors, molecular and structural biology and genetic regulation, viral oncology, vaccine development, transplantation, chemotherapy, clinical trial design, management and evaluation, pharmacology, drug development and developmental therapeutics, genetic and immunotherapies, pathology, diagnostic research and cytogenetics, biological response modifiers, imaging, nutrition, survey research, epidemiology, biostatistics, rehabilitation, psychology and behavioral medicine, public health and community oncology, quality of life, pain management, cancer detection and diagnosis, cancer treatment and restorative care, dentistry, nursing, public health, nutrition, education of health professionals, medical oncology, surgery, radiotherapy, gynecologic oncology, pediatric oncology, pathology, and biostatistics. Geographical, gender, ethnic and racial considerations are addressed in selecting members for appointment to the Board.
How frequent & relevant are cmte mtgs?*Meetings are held not less than three times a year. The committee met three times during this reporting period. The Board met jointly with the National Cancer Advisory Board for the December 2018 and June 2019 meetings. The Board also met in March 2019. The Board’s deliberations are an indispensable part of the review of a very large part of the Institute’s extramural program, as well as concept review of grant and contract initiatives in the extramural research program. According to the Board’s charter, approximately three formal meetings are held each year for the review of the extramural programs and concept review of Request for Applications (RFAs); cooperative agreements; and research and development contracts. The BSA ad hoc Subcommittee on HIV/AIDS Malignancy met on 24 May 2019. The BSA ad hoc Working Group on Immunology of Therapies and Vaccines and Research Structure met on 8 November 2018. The BSA ad hoc Working Group on Prevention met on 11 September and 19 September 2019.
Why advice can't be obtained elsewhere?*This Board is composed of recognized biomedical research authorities from outside the NIH in order to secure unbiased and objective evaluations of extramural research programs. Their recommendations are invaluable because the complex nature of the research requires a unique balance and breadth of expertise not available at NIH or from other established sources.
Why close or partially close meetings?N/A
Recommendation RemarksMembers: The terms for Kenneth Anderson and Dafna Bar-Sagi have changed due to reappointments. The terms for Graham Colditz, Diane Quale, Eileen White, and Kevin White have changed due to administrative extensions. As such, their term of service end dates are different than what was reported on the FY18 ACR.

Costs: The decrease in Federal Staff costs in FY19 was due to incorrectly reported salaries in the FY18 ACR. The increase in operating costs for FY19 was due to all BSA meetings being held in person and an increase in working group meetings.

The DFO and Committee Decision Maker positions are held by the same individual because of the assignment of responsibilities within the Institute.
Hide Section - PERFORMANCE MEASURES

PERFORMANCE MEASURES

Outcome Improvement To Health Or Safety*YesAction Reorganize Priorities*Yes
Outcome Trust In GovernmentNoAction Reallocate ResourcesYes
Outcome Major Policy ChangesNoAction Issued New RegulationsNo
Outcome Advance In Scientific ResearchYesAction Proposed LegislationNo
Outcome Effective Grant MakingNoAction Approved Grants Or Other PaymentsNo
Outcome Improved Service DeliveryNoAction OtherNo
Outcome Increased Customer SatisfactionNoAction CommentPriorities are reorganized based on motions made by Board members regarding RFA and RFP concepts. Resources are allocated based on approved concepts.
Outcome Implement Laws/Reg RequirementsNoGrants Review*No
Outcome OtherYesNumber Of Grants Reviewed0
Outcome CommentBased on the approval of the various RFA and RFP concepts, significant advances in cancer research could lead to new treatments, prevention and control initiatives, and behavioral modifications and cures for different cancer sites. Another outcome is the annual posting of the RFA Report.Number Of Grants Recommended0
Cost Savings*Unable to DetermineDollar Value Of Grants Recommended$0.00
Cost Savings CommentMeetings are held not less than three times a year. The committee met three times during this reporting period. The Board met jointly with the National Cancer Advisory Board for the December 2018 and June 2019 meetings. The Board also met in March 2019. Additionally, RFA and RFP concepts are reviewed annually to determine the need for reissuance based on the Board recommendations. Ad hoc Subcommittee and/or working group meetings are held to gather information. Recommendations are reported back at a full board meeting where advice is given to the Institute. The BSA supports the Institute in meeting its mission and as a result even though it can’t be calculated, there are substantive savings.Grants Review CommentNA
Number Of Recommendations*324Access Contact Designated Fed. Officer*Yes
Number Of Recommendations Comment1. A motion to concur on the Division of Cancer Biology’s (DCB’s) requests for applications (RFA) entitled “Cellular Cancer Biology Imaging Research Resource Program” was approved was approved with 15 ayes, 1 nay, and no abstentions, with the stipulation that the central theme of the RFA be cancer biology-focused. 2. A motion to concur on the Division of Cancer Treatment and Diagnosis’ (DCTD’s) RFA entitled “Molecular and Biological Effects of High Linear Energy Transfer Radiation Exposure” was approved unanimously. 3. A motion to concur on the Office of the Director’s (OD’s) RFA/Cooperative Agreement (Coop. Agr.) entitled “Informatics Technology for Cancer Research” was approved unanimously. 4. A motion to concur on the Division of Cancer Control and Population Science’s (DCCPS’) RFA entitled “Optimizing Management and Outcomes for Cancer Survivors Transitioning to Follow-up Care” was approved unanimously. 5. A motion to concur on the DCCPS’ RFA entitled “Research on Pediatric, Adolescent, and Young Adult Survivorship Through the Childhood Cancer Survivorship, Treatment, Access and Research (STAR) Act” was approved unanimously. 6. A motion to concur on the one-time issuance of OD’s RFA entitled “Advancing Cancer Immunotherapy by Mitigating Immune-Related Adverse Events” was approved unanimously. 7. A motion to concur on the one-time issuance of DCCPS’ RFA/Coop. Agr. entitled “Patient Engagement for Priority Cancer Sequencing (PE4PC-Seq)” was approved unanimously. 8. A motion to defer on the OD’s RFA/Coop. Agr./Request for Proposal (RFP) entitled “Technologies Development for Use in Next Generation Cancer Models” was approved with 15 ayes, 1 nay, and no abstentions. 9. A motion to approve the 2021 BSA meeting dates was approved unanimously. 10. A motion to concur with establishing a BSA ad hoc Working Group on Prevention was approved unanimously. 11. A motion to approve the BSA exception concurrence for indefinite re-issuance of select Program Announcements with Special Receipt, Referral, and/or Review (PARs), including generic training and diversity funding opportunity announcements (FOAs), and other FOAs was approved unanimously. 12. A motion to concur on the DCCPS’ re-issue RFA/Coop. Agr. (Clinical Trials Not Allowed) entitled “Cancer Intervention and Surveillance Modeling Network (CISNET)” was approved with 22 ayes, zero nays, and 1 abstention. 13. A motion to concur on the OD’s re-issue RFA/Coop. Agr. (Limited Competition) entitled “AIDS Malignancy Consortium (AMC)” was approved unanimously. 14. A motion to concur on the DCTD’s re-issue RFP entitled “Cancer Trials Support Unit” was approved unanimously. 15. A motion to concur on the OD’s RFP entitled “Small Business Innovation Research (SBIR) Contract Topics” was approved with 22 ayes, zero nays, and 1 abstention. 16. A motion to concur on the DCCPS’ PAR (Clinical Trials Optional) entitled “Clinical Characterization of Cancer Therapy-Induced Adverse Sequelae and Mechanism-based Interventional Strategies” was approved unanimously. 17. A motion to concur on the OD’s RFA/Administrative Supplement entitled “Activities to Promote Human Immune-Representing Oncology Models Initiative” was approved unanimously. 18. A motion to concur on the OD’s RFA/Coop. Agr. entitled “Next Gen Technology for Next Gen Cancer Models” was approved unanimously. 19. A motion to concur on the OD’s RFA entitled “Mechanisms of Cancer Drug Resistance Competing Revisions” was approved with 19 ayes, zero nays, and 1 abstention. 20. A motion to accept the change in the December 2019 meeting dates of the NCAB and BSA was approved unanimously. 21. A motion to accept the minutes of the 25 March 2019 BSA meeting was approved unanimously. 22. A motion to accept the final report of the BSA ad hoc Working Group on Immunology of Therapies & Vaccines and Research Structure was approved unanimously. 23. A motion to concur on the DCTD’s re-issue RFA/Coop. Agr. (Limited Competition) entitled “Pediatric Brain Tumor Consortium” was approved with 14 ayes, zero nays, and 2 abstentions. 24. A motion to concur on the DCTD’s RFP entitled “Clinical Trials Information and Management Contract” was approved with 15 ayes, zero nays, and 1 abstention. 25. A motion to concur on the Division of Cancer Prevention’s (DCP’s) re-issue RFA/Coop. Agr. entitled “Chronic Pancreatitis, Diabetes, and Pancreatic Cancer Consortium” was approved with 7 ayes, 6 nays, and 3 abstentions. 26. A motion to concur on the OD’s RFA/Coop. Agr. entitled “U.S. and Low- and Middle-Income Country (LMIC) HIV Malignancy Research Networks” was approved unanimously. 27. A motion to concur on the DCTD’s re-issue RFA/Coop. Agr. (Limited Competition) entitled “Biospecimen Banks to Support NCI National Clinical Trials Network (NCTN), NCI Community Oncology Research Program (NCORP), and CTEP-Supported Early Trials/Studies” was approved unanimously. 28. A motion to concur on the DCCPS’ PAR entitled “Co-Infection and Cancer” was approved unanimously. 29. A motion to concur on the re-issue of 17 PARs was approved unanimously.Access Agency WebsiteYes
% of Recs Fully Implemented*90.00%Access Committee WebsiteYes
% of Recs Fully Implemented CommentThe percentage of recommendations implemented as stated above was developed at the time the Annual Comprehensive Review report was prepared. Additional information is available through the RePORT (Research Portfolio Online Reporting Tool) website. RePORT provides access to reports, data, and analyses of NIH research activities that advance the mission of the NIH, including information on NIH expenditures, strategic plans, reports on NIH funding, and reports on the organization and people involved in NIH research and research training. The RePORT website is located at http://report.nih.govAccess GSA FACA WebsiteYes
% of Recs Partially Implemented*10.00%Access PublicationsYes
% of Recs Partially Implemented CommentThe percentage of recommendations implemented stated above was developed at the time the Annual Comprehensive Review report was prepared. Additional information is available through the RePORT (Research Portfolio Online Reporting Tool) website. RePORT provides access to reports, data, and analyses of NIH research activities that advance the mission of the NIH, including information on NIH expenditures, strategic plans, reports on NIH funding, and reports on the organization and people involved in NIH research and research training. The RePORT website is located at http://report.nih.gov.Access OtherYes
Agency Feedback*YesAccess CommentInformation on the BSA can be found at the NCI Division of Extramural Activities: Advisory Boards, Committees and Review Groups website at http://deainfo.nci.nih.gov/advisory/bsa/bsa.htm. Each NCI committee’s charter, minutes, agenda, roster, future meeting dates, meeting PowerPoint presentations and reports is located here. Additionally, the public may view the BSA meetings (both live and on demand) via the NIH Videocast at the following website: http://videocast.nih.gov/.
Agency Feedback CommentThe NCI Director’s Report is presented at each Board meeting. Each NCI Division gives an update regarding progress of approved RFAs, cooperative agreements and contract concepts. Also, the Annual RFA Report is presented at each November/December Joint BSA/National Cancer Advisory Board meeting to show RFAs published and reviewed. A list of action items are assigned to individual NCI staff with specific time frames with deadlines.Narrative Description*The goal of NIH research is to acquire new knowledge to help prevent, detect, diagnose, and treat disease and disability, from the rarest genetic disorder to the common cold. The NIH mission is to uncover new knowledge that will lead to better health for everyone. NIH works toward that mission by the National Cancer Institute Board of Scientific Advisor’s (BSA). The BSA is composed of distinguished scientists from outside the NCI and representatives from the advocacy community. The BSA provides scientific advice on a wide variety of matters concerning scientific program policy, reviews the progress and future direction of the extramural research programs, and concept review of extramural program initiatives. This includes the oversight of research and development, concept review of request for applications, cooperative agreements, initiatives and other programmatic activities. The advisory role of the BSA is scientific and does not include deliberation on matters of public policy. The BSA represents the scientific community's voice in the extramural science the NCI supports. As such, the Board advises the NCI leadership on the progress and future direction of the Institute's Extramural Research Program. The Board evaluates NCI extramural programs, and reviews ideas for new research opportunities and solicitations to ensure that a concept is meritorious and consistent with the Institute's mission. Additionally, the BSA believes it is important to interact with and receive feedback from the clinical, population science, and laboratory research communities affected by NCI policies. The BSA’s deliberations are an indispensable part of the review of a very large part of the Institute's extramural program.
Hide Section - COSTS

COSTS

Payments to Non-Federal Members*$11,200.00Est Payments to Non-Fed Members Next FY*$11,200.00
Payments to Federal Members* Est. Payments to Fed Members Next FY* 
Payments to Federal Staff*$64,766.00Estimated Payments to Federal Staff*$61,432.00
Payments to Consultants* Est. Payments to Consultants Next FY* 
Travel Reimb. For Non-Federal Members*$38,113.00Est Travel Reimb Non-Fed Members nextFY*$38,362.00
Travel Reimb. For Federal Members* Est Travel Reimb For Fed Members* 
Travel Reimb. For Federal Staff* Est. Travel Reimb to Fed Staff Next FY* 
Travel Reimb. For Consultants* Est Travel Reimb to Consultants Next FY* 
Other Costs$94,652.00Est. Other Costs Next FY*$95,599.00
Total Costs$208,731.00Est. Total Next FY*$206,593.00
Federal Staff Support (FTE)*0.40Est. Fed Staff Support Next FY*0.30
Hide Section - Custom Links

Custom Links

     Committee Level Reports               
Hide Section - MEMBERS,MEETINGS AND ADVISORY REPORTS

MEMBERS,MEETINGS AND ADVISORY REPORTS

To View all the members, meetings and advisory reports for this committee please click here
Hide Section - CHARTERS AND RELATED DOCS

CHARTERS AND RELATED DOCS

No Documents Found
Hide Section - DATA FROM PREVIOUS YEARS

DATA FROM PREVIOUS YEARS

Committee

Data from Previous Years

 
ActionCommittee System IDCommittee NameFiscal Year
 COM-001923National Cancer Institute Board of Scientific Advisors2017
 COM-002258National Cancer Institute Board of Scientific Advisors2016
 COM-004079National Cancer Institute Board of Scientific Advisors2015
 COM-004408National Cancer Institute Board of Scientific Advisors2014
 COM-006156National Cancer Institute Board of Scientific Advisors2013
 COM-006867National Cancer Institute Board of Scientific Advisors2012
 COM-008324National Cancer Institute Board of Scientific Advisors2011
 COM-009069National Cancer Institute Board of Scientific Advisors2010
 COM-010116National Cancer Institute Board of Scientific Advisors2009
 COM-011002National Cancer Institute Board of Scientific Advisors2008
 COM-012119National Cancer Institute Board of Scientific Advisors2007
 COM-012487National Cancer Institute Board of Scientific Advisors2006
 COM-013962National Cancer Institute Board of Scientific Advisors2005
 COM-014543National Cancer Institute Board of Scientific Advisors2004
 COM-016033National Cancer Institute Board of Scientific Advisors2003
 COM-016593National Cancer Institute Board of Scientific Advisors2002
 COM-017634National Cancer Institute Board of Scientific Advisors2001
 COM-018354National Cancer Institute Board of Scientific Advisors2000
 COM-019571National Cancer Institute Board of Scientific Advisors1999
 COM-020365National Cancer Institute Board of Scientific Advisors1998
 COM-021711National Cancer Institute Board of Scientific Advisors1997
 COM-034777National Cancer Institute Board of Scientific Advisors2018